Scale up of a lentiviral production process from the iCELLis®️ Nano Bioreactor to the iCELLis 500+ Bioreactor

Cell & Gene Therapy Insights 2021; 7(9), 1023


Published: 22 September 2021
Isabelle Pelletier, Kaitlynn Bayne

Watch the video or read the poster to learn:

  • The challenges of lentivirus production.
  • The advantages of the iCELLis fixed bed bioreactor, an automated, single-use, fixed-bed bioreactor that provides excellent conditions for viral vector production in adherent cells.
  • Proven performance of the iCELLis Nano bioreactor and the iCELLis 500+ bioreactor

Isabelle Pelletier has more than 20 years of experience in the biopharmaceutical industry and joined ABL in 2018. She specializes in cell culture, viral vectors and upstream process optimization. Isabelle holds a bachelor’s degree in Biochemistry from the Université Laval

Kaitlynn Bayne is an Application Specialist within the Scientific and Laboratory Services (SLS) team at Pall Corporation. She has experience with cell culture, bioreactors, analytics, and assay development. Kaitlynn obtained her Master’s Degree in Molecular, Cellular, and Developmental Biology from the University of Michigan and has over five years of laboratory experience including positions at the University of Michigan and Pall.